Avadel settled with Jazz Pharmaceuticals, clearing legal hurdles for Alkermes' $20/share acquisition. Click to read my update ...

Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Alkermes plc ALKS announced that it has entered into a definitive agreement to acquire Ireland-based Avadel Pharmaceuticals ...

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The ...

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

ABSTRACT: Background: To delay the onset of dementia with age, it is important for healthy adults to take preventive measures before cognitive decline occurs. Cognitive function decline is often ...

Hello, everyone, and welcome to this investor call to discuss oveporexton Phase III data and commercial readiness. My name is Christopher O'Reilly, Head of Investor Relations at Takeda. Today's ...

TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...